Drug Trial Radar · NCT06405087
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Oct 27, 2025
Primary completion
Aug 12, 2030
Study completion Aug 12, 2030
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- May 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main aim of this study is to learn about medical problems (adverse events) if vedolizumab subcutaneously (SC) is given to a child or teenager with UC or CD for a long time. Other aims are to understand if the long time use of vedolizumab SC has an impact on the time period until hospital visits because of bowel swelling (inflammation) are needed and has an impact on the quality of life of children and teenagers who received vedolizumab SC. In this study, participants who responded well to the treatment with vedolizumab SC in the parent study (VedolizumabSC-3003 \[NCT06100289\]) will continue to be treated with vedolizumab SC. Participants who did not respond well to the treatment with vedolizumab SC in the parent study or who received corticosteroids in the last 4 weeks of the parent study will not receive vedolizumab SC in this study but will be followed for up to 2 years after the last treatment with vedolizumab SC in the parent study. During the study, participants will visit their study clinic several times.
Conditions
- Ulcerative Colitis
- Crohn's Disease
Interventions
Vedolizumab SCDrug
Vedolizumab subcutaneous injection.
No InterventionOther
As this is an observational cohort, no intervention will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment Cohort: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: First dose of the study drug until 18 weeks of follow-up after last dose (up to Week 138)
- Treatment Cohort: Number of Participants With Adverse Events of Special Interests (AESIs)Time frame: First dose of the study drug until 18 weeks of follow-up after last dose (up to Week 138)
- Observational Cohort: Number of Participants With Prespecified Safety EventsTime frame: Up to Week 86
Locations
45 sites in 14 countries. Site status is shown where the registry gives one.
Phoenix Childrens Hospital
Phoenix, Arizona · Not yet recruiting
Loma Linda University
Loma Linda, California · Not yet recruiting
Children's Hospital of Orange County
Orange, California · Not yet recruiting
Advocate Children's Hospital Park Ridge
Park Ridge, Illinois · Not yet recruiting
Childrens Hospital of Michigan
Detroit, Michigan · Not yet recruiting
Atlantic Health - Morristown Medical Center
Morristown, New Jersey · Not yet recruiting
New York Presbyterian Hospital
New York, New York · Not yet recruiting
University Children's Clinic
Cleveland, Ohio · Not yet recruiting
Cleveland Clinic
Cleveland, Ohio · Not yet recruiting
The University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma · Recruiting
Penn State Health Milton South Hershey Medical Center
Hershey, Pennsylvania · Not yet recruiting
Medical University of South Carolina
Charleston, South Carolina · Not yet recruiting
Multicare Health System Institute for Research and Innovation
Tacoma, Washington · Not yet recruiting
Centre Hospitalier Chretien MontLegia
Liège, Belgium · Not yet recruiting
Cliniques Universitaires Saint-Luc
Brussels, Brussels Capital, Belgium · Not yet recruiting
UMHAT Sv. Georgi, EAD
Plovdiv, Bulgaria · Recruiting
Childrens Health Ireland at Crumlin - PIN
Crumlin, Dublin, Ireland · Not yet recruiting
Azienda Ospedaliera Universitaria Gaetano Martino, Messina
Messina, Italy · Not yet recruiting
ASST Fatebenefratelli Sacco - Ospedale dei Bambini Vittore Buzzi - INCIPIT - PIN
Milan, Italy · Not yet recruiting
Unita Operativa Complessa Di Pediatria Medica
Pescara, Italy · Not yet recruiting
Bambin Gesu Hospital - Ospedale Pediatrico Bambin Gesu
Roma, Italy · Not yet recruiting
Kurume University Hospital
Kurume-shi, Fukuoka, Japan · Not yet recruiting
Juntendo University Hospital
Bunkyo-ku, Tokyo, Japan · Recruiting
National Center for Child Health and Development
Setagaya-ku, Tokyo, Japan · Not yet recruiting
Radboud Universitair Medisch Centrum
Nijmegen, Netherlands · Not yet recruiting
Korczowski Bartosz, Gabinet Lekarski
Rzeszów, Poland · Recruiting
WIP Warsaw IBD Point Profesor Kierkus
Warsaw, Poland · Recruiting
Instytut Pomnik - Centrum Zdrowia Dziecka
Warsaw, Poland · Recruiting
Grigore Alexandrescu Emergency Clinical Hospital for Children
Bucharest, Romania · Recruiting
Victor Gomoiu Clinical Hospital for Children
Bucharest, Bucharest, Romania · Recruiting
University Children's Clinic
Belgrade, Serbia · Not yet recruiting
Institute for Children and Youth Health Care of Vojvodina
Novi Sad, Serbia · Not yet recruiting
Kyungpook National University Chilgok hospital
Daegu, South Korea · Recruiting
Severance Hospital, Yonsei University Health System
Seoul, South Korea · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Not yet recruiting
Hospital Arquitecto Marcide de Ferrol
Ferrol, Spain · Not yet recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Not yet recruiting
Hospital Universitario Virgen Macarena
Seville, Spain · Not yet recruiting
Universitat de Valencia - Hospital Universitari i Politecnic La Fe de Valencia (Hospital La Fe Bulevar Sur)
Valencia, Spain · Not yet recruiting
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.